GRAIL (GRAL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on GRAIL (GRAL) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.14 of bullish evidence against -0.29 bearish.

GRAIL last closed at $137.28, -10.90% on the session.

Against the IVW growth benchmark the position is -11.51% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

17 graded predictions for GRAL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks GRAIL in the 29th percentile on return on equity, where 100 is best.

GRAIL is classified under Health Care / Biotechnology, with a market capitalisation of $6.88B.

StockMap tracks GRAIL as the 40th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite GRAIL ranks 207th of 365 in the group, against a group median of -0.21.